Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study.
Twenty-three previously treated patients with malignant gliomas were included in this phase II study of carboplatin (400 mg/m2) given as an intraarterial infusion every 4 weeks. Five patients (26% of 19 evaluable) achieved a partial response for 3 to 10 months and 5 patients presented a stabilization for 2 to 7 months. Toxicity was mild in most patients, with nausea, vomiting and myelosuppression being the most frequent side-effects. No renal or auditory toxicity was observed. One patient developed central nervous toxicity and another one a reversible fall in visual acuity. Finally, carboplatin infused by the intraarterial route seems to be an active drug, less toxic than cisplatin, in malignant gliomas, and further trials are warranted.
Follézou
J Y
JY
Université Pierre et Marie Curie, Hôpital de la Pitié-Salpêtrière, Paris, France.
Fauchon
F
F
Chiras
J
J
D000328:Adult; D001254:Astrocytoma / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016190:Carboplatin; D002945:Cisplatin / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005909:Glioblastoma / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin